{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:01:03Z","timestamp":1777510863490,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"SEAM-PsA trial"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To examine which composite measures are most sensitive to change when measuring psoriatic arthritis (PsA) disease activity, analyses compared the responsiveness of composite measures used in a 48-week randomized, controlled trial of MTX and etanercept in patients with PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The trial randomised 851 patients to receive weekly: MTX (20\u2009mg\/week), etanercept (50\u2009mg\/week) or MTX plus etanercept. Dichotomous composite measures examined included ACR 20\/50\/70 responses, minimal disease activity (MDA) and very low disease activity (VLDA). Continuous composite measures examined included Disease Activity Score (28 joints) using CRP (DAS28-CRP), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), Disease Activity for Psoriatic Arthritis (DAPSA) and Psoriatic Arthritis Disease Activity Score (PASDAS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 24, etanercept-treated groups were significantly more effective than MTX monotherapy to achieve ACR 20 (primary end point) and MDA (key secondary end point). When examining score changes from baseline at week 24 across the five continuous composite measures, PASDAS demonstrated relatively greater changes in the etanercept-treated groups compared with MTX monotherapy and had the largest effect size and standardized response. Joint count changes drove overall score changes at week 24 from baseline in all the continuous composite measures except for PASDAS, which was driven by the Physician and Patient Global Assessments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PASDAS was the most sensitive continuous composite measure examined with results that mirrored the protocol-defined primary and key secondary outcomes. Composite measures with multiple domains, such as PASDAS, may better quantify change in PsA disease burden.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trail registration<\/jats:title>\n                  <jats:p>https:\/\/ClinicalTrials.gov, number NCT02376790.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa271","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T03:20:43Z","timestamp":1588044043000},"page":"1137-1147","source":"Crossref","is-referenced-by-count":13,"title":["Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Clinical Research, Swedish Medical Center\/Providence St. Joseph Health and the University of Washington, Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Division of Immunology\/Rheumatology, Stanford University, Palo Alto, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonieke J J","family":"van Mens","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyrica","family":"Liu","sequence":"additional","affiliation":[{"name":"Global Biostatistical Science, Amgen Inc., South San Francisco, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla K","family":"Yen","sequence":"additional","affiliation":[{"name":"Global Biostatistical Science, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H","family":"Collier","sequence":"additional","affiliation":[{"name":"US Medical Organization, Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Kricorian","sequence":"additional","affiliation":[{"name":"US Medical Organization, Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B","family":"Chung","sequence":"additional","affiliation":[{"name":"US Medical Organization, Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip S","family":"Helliwell","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,30]]},"reference":[{"key":"2021030705491795000_keaa271-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2021030705491795000_keaa271-B2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/1468-0009.12165","article-title":"Composite measures of health care provider performance: a description of approaches","volume":"93","author":"Shwartz","year":"2015","journal-title":"Milbank Q"},{"key":"2021030705491795000_keaa271-B3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.22204","article-title":"Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab","volume":"66","author":"Helliwell","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2021030705491795000_keaa271-B4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2021030705491795000_keaa271-B5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2021030705491795000_keaa271-B6","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021030705491795000_keaa271-B7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/art.40391","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis\/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021030705491795000_keaa271-B8","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021030705491795000_keaa271-B9","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021030705491795000_keaa271-B10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.2010.129379","article-title":"Development of a preliminary composite disease activity index in psoriatic arthritis","volume":"70","author":"Mumtaz","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021030705491795000_keaa271-B11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/rheumatology\/kez215","article-title":"Comparison of disease activity measures in early psoriatic arthritis in usual care","volume":"58","author":"Wervers","year":"2019","journal-title":"Rheumatology"},{"key":"2021030705491795000_keaa271-B12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3899\/jrheum.170449","article-title":"Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature","volume":"45","author":"Gossec","year":"2018","journal-title":"J Rheumatol"},{"key":"2021030705491795000_keaa271-B13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021030705491795000_keaa271-B14","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/annrheumdis-2017-211137","article-title":"The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial","volume":"76","author":"Coates","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021030705491795000_keaa271-B15","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021030705491795000_keaa271-B16","doi-asserted-by":"crossref","first-page":"e000606","DOI":"10.1136\/rmdopen-2017-000606","article-title":"Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"key":"2021030705491795000_keaa271-B17","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study (Caspar Study Group)","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021030705491795000_keaa271-B18","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M","article-title":"Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?","volume":"41","author":"Felson","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2021030705491795000_keaa271-B19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","article-title":"Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort","volume":"77","author":"van Mens","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021030705491795000_keaa271-B20","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2021030705491795000_keaa271-B21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology"},{"key":"2021030705491795000_keaa271-B22","author":"Helliwell","year":"2017"},{"key":"2021030705491795000_keaa271-B23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-018-1739-0","article-title":"Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease","volume":"20","author":"Helliwell","year":"2018","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/3\/1137\/36434018\/keaa271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/3\/1137\/36434018\/keaa271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T05:53:36Z","timestamp":1615096416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/3\/1137\/5899313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,30]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,8,30]]},"published-print":{"date-parts":[[2021,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa271","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,8,30]]}}}